Skip to content
Disclosery

TRV GP V, LLC

Follow

13F filer, CIK 1990717, Boston, MA

TRV GP V, LLC reported $401,003,472 across 3 holdings for the quarter ended 2026-03-31, in a 13F-HR filed 2026-05-07.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001193125-26-212010

Period
2026-03-31
Reported value
$401M
Holdings
3
Top 10 weight
100%
New
0
Sold out
0

Holdings, Q1 2026

Share positions as resolved from 13F-HR 0001193125-26-212010, largest first. % of portfolio is the value over $401,003,473, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
RAPPRAPPORT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 7,135,233 shares; 2025Q1: 7,135,233 shares; 2025Q2: 7,135,233 shares; 2025Q3: 7,135,233 shares; 2025Q4: 7,135,233 shares; 2026Q1: 7,135,233 shares 7,135,233$223M55.68%0Timeline
SEPNSEPTERNA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 6,215,591 shares; 2025Q1: 6,215,591 shares; 2025Q2: 6,215,591 shares; 2025Q3: 6,215,591 shares; 2025Q4: 6,215,591 shares; 2026Q1: 6,215,591 shares 6,215,591$149M37.25%0Timeline
MAZEMAZE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: 950,800 shares; 2025Q2: 950,800 shares; 2025Q3: 950,800 shares; 2025Q4: 950,800 shares; 2026Q1: 950,800 shares 950,800$28.4M7.08%0Timeline

How Q1 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001193125-26-212010 base2026-05-07acceptance time not in the bulk data set